JP2023547323A5 - - Google Patents

Info

Publication number
JP2023547323A5
JP2023547323A5 JP2023519662A JP2023519662A JP2023547323A5 JP 2023547323 A5 JP2023547323 A5 JP 2023547323A5 JP 2023519662 A JP2023519662 A JP 2023519662A JP 2023519662 A JP2023519662 A JP 2023519662A JP 2023547323 A5 JP2023547323 A5 JP 2023547323A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
antigen
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023519662A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023547323A (ja
JP7767411B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/056018 external-priority patent/WO2022087243A1/en
Publication of JP2023547323A publication Critical patent/JP2023547323A/ja
Publication of JP2023547323A5 publication Critical patent/JP2023547323A5/ja
Application granted granted Critical
Publication of JP7767411B2 publication Critical patent/JP7767411B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023519662A 2020-10-22 2021-10-21 抗fgfr2抗体及びその使用方法 Active JP7767411B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063104377P 2020-10-22 2020-10-22
US63/104,377 2020-10-22
US202163220948P 2021-07-12 2021-07-12
US63/220,948 2021-07-12
US202163253858P 2021-10-08 2021-10-08
US63/253,858 2021-10-08
PCT/US2021/056018 WO2022087243A1 (en) 2020-10-22 2021-10-21 Anti-fgfr2 antibodies and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2023547323A JP2023547323A (ja) 2023-11-10
JP2023547323A5 true JP2023547323A5 (https=) 2024-10-17
JP7767411B2 JP7767411B2 (ja) 2025-11-11

Family

ID=78806631

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023519662A Active JP7767411B2 (ja) 2020-10-22 2021-10-21 抗fgfr2抗体及びその使用方法

Country Status (13)

Country Link
US (2) US11866502B2 (https=)
EP (1) EP4232481A1 (https=)
JP (1) JP7767411B2 (https=)
KR (1) KR20230095070A (https=)
CN (1) CN116406379A (https=)
AU (1) AU2021366691B2 (https=)
CA (1) CA3190569A1 (https=)
CL (1) CL2023001114A1 (https=)
CO (1) CO2023004110A2 (https=)
IL (1) IL301702A (https=)
MX (1) MX2023004434A (https=)
NZ (1) NZ797493A (https=)
WO (1) WO2022087243A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7590328B2 (ja) * 2018-12-21 2024-11-26 レゲネロン ファーマシューティカルス,インコーポレーテッド ツブリシン及びタンパク質-ツブリシンコンジュゲート
CA3190569A1 (en) 2020-10-22 2022-04-28 Christopher Daly Anti-fgfr2 antibodies and methods of use thereof
CN117917435A (zh) * 2022-10-21 2024-04-23 北京天广实生物技术股份有限公司 结合fgfr2b的抗体及其用途
KR20250126131A (ko) * 2022-12-28 2025-08-22 쑤저우 트랜스센타 테라퓨틱스 컴퍼니 리미티드 항-fgfr2b 항체 및 이의 용도
WO2024240107A1 (zh) * 2023-05-19 2024-11-28 广东东阳光药业股份有限公司 一种抗fgfr2抗体及其应用
WO2025067442A1 (zh) * 2023-09-28 2025-04-03 南京维立志博生物科技股份有限公司 抗fgfr2抗体和包含其的多特异性结合分子
TW202540177A (zh) * 2023-11-14 2025-10-16 大陸商蘇州創勝醫藥集團有限公司 抗-FGFR2b免疫偶聯物及其於治療癌症的用途
WO2025130905A1 (zh) * 2023-12-18 2025-06-26 山东先声生物制药有限公司 抗FGFR2b抗体-药物缀合物及其应用
WO2025130860A1 (zh) * 2023-12-18 2025-06-26 山东先声生物制药有限公司 抗FGFR2b抗体及其应用
CN120424212A (zh) * 2024-01-26 2025-08-05 上海安领科生物医药有限公司 抗FGFR2b抗体及抗体药物偶联物
WO2025209434A1 (zh) * 2024-04-01 2025-10-09 思康睿奇(上海)药业有限公司 抗FGFR2b抗体药物偶联物及其应用
WO2025218662A1 (zh) * 2024-04-16 2025-10-23 杭州中美华东制药有限公司 抗成纤维细胞生长因子受体2b的抗体及其用途
WO2026007196A1 (zh) * 2024-07-02 2026-01-08 安博泰克药业有限公司 特异性结合FGFR2b的抗体及其与药物的缀合物

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1231260B (it) 1988-11-16 1991-11-28 Sergio Bertini Curri Farmaco e metodo per aumentare volume e velocita' del flusso microcircolatorio capillare a livello cutaneo
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20070258987A1 (en) 2000-11-28 2007-11-08 Seattle Genetics, Inc. Recombinant Anti-Cd30 Antibodies and Uses Thereof
CA2556752C (en) 2004-02-23 2016-02-02 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
AR048098A1 (es) 2004-03-15 2006-03-29 Wyeth Corp Conjugados de caliqueamicina
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトil−6受容体に対する高親和性抗体
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
WO2008122039A2 (en) 2007-04-02 2008-10-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selenocysteine mediated hybrid antibody molecules
EP2167963B1 (en) 2007-05-23 2019-04-17 Ventana Medical Systems, Inc. Polymeric carriers for immunohistochemistry and in situ hybridization
SG189817A1 (en) 2008-04-30 2013-05-31 Immunogen Inc Potent conjugates and hydrophilic linkers
AU2009275358C1 (en) 2008-07-21 2015-09-24 Polytherics Limited Novel reagents and method for conjugating biological molecules
HUE035700T2 (en) 2008-11-07 2018-05-28 Galaxy Biotech Llc Monoclonal antibodies to Fibroblast Growth Factor receptor 2
KR101000067B1 (ko) 2008-12-30 2010-12-10 엘지전자 주식회사 고효율 태양전지용 레이저 소성장치 및 고효율 태양전지 제조방법
MY192182A (en) 2009-06-26 2022-08-04 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
AU2010283632B2 (en) 2009-08-10 2016-08-25 Ucl Business Plc Reversible covalent linkage of functional molecules
SMT202600080T1 (it) 2010-02-08 2026-03-09 Regeneron Pharma Topo con catena leggera comune
SI2528625T1 (sl) 2010-04-15 2013-11-29 Spirogen Sarl Pirolobenzodiazepini in njihovi konjugati
US20130244905A1 (en) 2010-07-06 2013-09-19 Ed Grabczyk Reporter for RNA Polymerase II Termination
CA2813411C (en) 2010-11-05 2016-08-02 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
CN110078789A (zh) 2011-05-27 2019-08-02 Ambrx 公司 含有非天然氨基酸连接的海兔毒素衍生物的组合物、涉及该海兔毒素衍生物的方法及其用途
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
BR112014009070B1 (pt) 2011-10-14 2021-11-23 Medimmune Limited Método de síntese e intermediários úteis na preparação de pirrolobenzo-diazepinas
CA2850373C (en) 2011-10-14 2019-07-16 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
EP2751111B1 (en) 2011-10-14 2017-04-26 MedImmune Limited Asymmetrical bis-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-5-one) derivatives for the treatment of proliferative or autoimmune diseases
CN103997893B (zh) 2011-10-14 2019-04-12 西雅图基因公司 吡咯并苯并二氮杂卓和靶向结合物
WO2013068874A1 (en) 2011-11-11 2013-05-16 Pfizer Inc. Antibody-drug conjugates
AR088941A1 (es) * 2011-11-23 2014-07-16 Bayer Ip Gmbh Anticuerpos anti-fgfr2 y sus usos
RU2014124984A (ru) 2011-12-05 2016-01-27 Идженика Биотерапьютикс, Инк. Конъюгаты антитело-лекарственное средство и родственные соединения, композиции и способы
CN105142672B (zh) 2012-10-23 2019-04-05 西纳福克斯股份有限公司 经修饰的抗体、抗体-缀合物及其制备方法
WO2014089193A1 (en) * 2012-12-04 2014-06-12 Aveo Pharmaceuticals, Inc. Anti-fgfr2 antibodies
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
JP6847388B2 (ja) 2013-03-15 2021-03-31 レゲネロン ファーマシューティカルス,インコーポレーテッド 生物活性分子、そのコンジュゲート、及び治療用途
KR102516152B1 (ko) 2013-08-01 2023-03-31 파이브 프라임 테라퓨틱스, 인크. 비푸코실화된 항-fgfr2iiib 항체
BR112016004023A2 (pt) 2013-08-26 2022-11-16 Regeneron Pharma Composição, métodos para preparar uma composição e para tratar uma doença, e, composto
KR102445502B1 (ko) 2014-04-10 2022-09-21 다이이찌 산쿄 가부시키가이샤 항her3 항체-약물 콘주게이트
SG11201608192SA (en) 2014-04-11 2016-10-28 Medimmune Llc Bispecific her2 antibodies
BR112017020149A8 (pt) 2015-03-27 2023-05-02 Regeneron Pharma Derivados de maitansinoide, conjugados dos mesmos e métodos de uso
BR112018014759B1 (pt) 2016-01-25 2024-02-27 Regeneron Pharmaceuticals, Inc Compostos derivados de maitasinoide e seus conjugados, composição compreendendo os mesmos, seus métodos de fabricação e uso
EP3419670A2 (en) 2016-02-26 2019-01-02 Regeneron Pharmaceuticals, Inc. Optimized transglutaminase site-specific antibody conjugation
WO2018044540A1 (en) 2016-08-31 2018-03-08 Regeneron Pharmaceuticals, Inc. Compositions and methods for detecting protein trafficking
ES3046537T3 (en) 2016-11-08 2025-12-02 Regeneron Pharma Steroids and protein-conjugates thereof
JP7590328B2 (ja) 2018-12-21 2024-11-26 レゲネロン ファーマシューティカルス,インコーポレーテッド ツブリシン及びタンパク質-ツブリシンコンジュゲート
KR20220119471A (ko) 2019-12-24 2022-08-29 디잘 (지앙수) 파마슈티칼 씨오., 리미티드 신규한 항fgfr2b 항체
CA3190569A1 (en) 2020-10-22 2022-04-28 Christopher Daly Anti-fgfr2 antibodies and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2023547323A5 (https=)
JP7330996B2 (ja) Cd73を標的とする抗体および抗体-薬物複合体、その製造方法と使用
JP7402807B2 (ja) グリピカン3抗体およびそのコンジュゲート
JP2023515941A5 (https=)
AU2016276751B2 (en) CD123 antibodies and conjugates thereof
CN105849126B (zh) 抗trop2抗体-药物偶联物
KR101529810B1 (ko) 항체-약물 접합체
CN110770256B (zh) 靶向axl的抗体及抗体-药物偶联物及其制备方法和用途
EP4087613A1 (en) Anti-slc34a2 antibodies, antibody drug conjugates, and methods of use thereof
JP2019536740A5 (https=)
TWI726217B (zh) 含有抗globo h抗體之抗體-藥物共軛物及其用途
JP2010535713A5 (https=)
KR20140139480A (ko) 항체-약물 접합체 및 관련 화합물, 조성물, 및 방법
KR102949500B1 (ko) 접합을 위한 폴리펩티드 복합체 및 이의 용도
JP2024544520A5 (https=)
JP7827624B2 (ja) 抗cea抗体-エキサテカン類似体複合体及びその医薬用途
JP2021523100A5 (https=)
JP7675818B2 (ja) 抗クローディン-18.2抗体及びその抗体薬物複合体
WO2024076514A1 (en) C-c chemokine receptor type 8 (ccr8) antagonist antibodies
TW202245844A (zh) 抗dll3抗體-藥物結合物
AU2003298794A2 (en) Recombinant immunotoxin and use in treating tumors
JP2024517760A (ja) 抗5t4抗体及びその使用
EP4725968A1 (en) Anti-gpc3 antibody or antigen-binding fragment and use thereof
JP2026512687A (ja) ヒト化l1cam抗体-薬物複合体
CN120829509A (zh) 抗ror1抗体、其免疫缀合物及其应用